NIH Awards $15 Million Grant to UCSF-CFAR
News Oct 18, 2012
The National Institutes of Health (NIH) has awarded more than $15 million over the next five years to the UCSF-Gladstone Center for AIDS Research (CFAR) to continue its pioneering translational AIDS research. It’s the sixth renewal of the center’s grant.
The UCSF-Gladstone CFAR, one of 21 federally funded such centers nationwide, provides strategic, educational and scientific services to HIV/AIDS researchers through pilot grants totaling approximately $750,000 per year.
The center conducts a nationally recognized mentoring program between well established UCSF faculty investigators and early career researchers pursuing HIV research at UCSF or affiliated institutes, and provides essential infrastructure through its clinical and population sciences, immunology, virology, specimen bank and pharmacology cores. It also provides support to more than $80 million of funded HIV/AIDS research at UCSF and affiliated institutions.
The UCSF-Gladstone CFAR has played a crucial role in maintaining and extending the leadership role of San Francisco in responding to the HIV epidemic since its inception as one of the first CFARs funded almost 25 years ago, said co-director Warner Greene, MD, PhD, director of the Gladstone Institute of Virology and Immunology and UCSF professor of medicine.
“We are a CFAR that seeks to be nimble and responsive, constantly asking where the field is moving and how we can help position our community to respond to new and emerging topics in HIV research,” Greene said.
Greene continued, “As an example of how our CFAR operates and its impact, one of the hottest topics in HIV right now is research towards a cure. HIV latency is one of the fundamental obstacles to achieving a cure.”
HIV latency is the processes through which HIV manages to hide and persist in various cells and tissues in HIV-infected persons even after many years of successful suppression of the virus using antiretroviral medication.
The UCSF-Gladstone CFAR provided initial pilot funding for HIV latency research in 2003, and the findings generated by that research led to the NIH awarding the first major HIV latency program project grant, Greene said.
The research conducted with that grant then helped lead to the NIH’s Delaney Collaborative initiative last year, providing $80 million to three collaboratories - two of which involved UCSF and Gladstone investigators - seeking to develop a cure for HIV, he added.
The center has succeeded in stimulating several advances in HIV/AIDS research, including:
• Delineating the biology of the APOBEC3G protein in anti-viral immunity;
• Boosting thymic function;
• Understanding changes in viral “fitness” as a result of antiretroviral drug resistance;
• Better diagnosis and understanding of atherosclerosis in HIV;
• Pioneering the use of anti-retroviral medications by HIV-negative individuals to prevent acquisition of HIV (pre-exposure prophylaxis); and
• Studying the interactions between HIV and malaria.
Furthering NIH’s Mission for AIDS Research
The mission of the NIH CFAR program, first funded in 1988, is “to support a multi-disciplinary environment that promotes basic, clinical, epidemiologic, behavioral and translational research in the prevention, detection and treatment of HIV infection and AIDS.”
Looking ahead, the center has identified three key areas of investigation:
• Implementation of combination prevention - the bundling of proven behavioral interventions with biomedical interventions such as pre-exposure prophylaxis, male circumcision and treatment to dramatically reduce the rates of new infections;
• Understanding how HIV infection affects and accelerates the aging process; and
• Finding a cure for those already infected.
CFAR co-director Paul Volberding, MD, director of the UCSF AIDS Research Institute and professor of medicine at UCSF, said the center has been focusing on work in Africa, where it held the first Sub-Saharan Africa CFAR Conference last year in Kampala, Uganda, bringing together 240 researchers from 19 domestic CFARs and collaborators from 13 African countries.
“One of the most rewarding directions our CFAR has taken in recent years has been in building international collaborations, chiefly in East Africa,” Volberding said. “While we are conducting research in many countries, we have built a strong focus in Uganda, Kenya and Tanzania."
On November 8, the center also will host the National Centers for AIDS Research Scientific Symposium, titled “CFAR and HIV Therapy at 25: Seeking an End to AIDS,” at the UCSF Mission Bay Conference Center.
Anthony S. Fauci, MD, director of National Institute of Allergy and Infectious Disease, will be giving the keynote address, and this event will include the recognition of two important silver anniversaries - the establishment of the CFAR network and the introduction of AZT, the first therapeutic for HIV.
Other emerging initiatives for the center include targeting health disparities domestically through partnering with the UCSF Center for AIDS Prevention and the San Francisco Department of Public Health and expanding community engagement by partnering with Project Inform and the Forum for Collaborative Research.
“Even though it is 25 years since our first CFAR grant and in many ways the epidemic has changed dramatically, we continue to work with the same urgency to overcome the challenges that HIV/AIDS poses in the Bay Area, nationally and around the world,” concluded Volberding.
The Discovery of Typhoid Toxin's Sweet Tooth Could Lead to New TreatmentsNews
"Our study shows that the typhoid toxin targets both the immune system and central nervous system... This represents a new paradigm in the infectious agents' incursion of the host." The new study shows how the toxin exclusively damages selected cells at the organism level, specifically seeking cells that express particular sugars because of their binding abilities.READ MORE
Single-Dose Vaccine Could Provide Faster Protection in Cholera EpidemicsNews
Each year there are more than three million cases of cholera worldwide, a disease transmitted through contaminated food and water that hits developing countries particularly hard. While the standard regimen for protecting against cholera with existing non-living oral cholera vaccines includes administering two doses over a two-week period, research now shows that giving a stronger single-dose of a live oral vaccine could be an effective tool in controlling outbreaks more quickly.READ MORE
Severity of Autoimmune Disease Influenced by Time of DayNews
Insights into how the body clock and time of day influence immune responses are revealed today. Understanding the effect of the interplay between 24-hour day-night cycles and the immune system may help inform drug-targeting strategies to alleviate autoimmune disease.